<DOC>
	<DOCNO>NCT00265031</DOCNO>
	<brief_summary>This study design test ( 1 ) whether BEACOPP dosage reduce baseline last 4 cycle without loss effectiveness , ( 2 ) whether consolidate irradiation necessary follow effective chemotherapy .</brief_summary>
	<brief_title>HD12 Advanced Stages</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Hodgkin´s lymphoma ( histologically proven ) CS ( PS ) IIB one risk factor : 1. bulky mediastinal mass ( &gt; 1/3 maximum transverse thorax diameter ) 2. extranodal involvement CS ( PS ) III , IV write informaed consent Leukocytes &lt; 3000/microl Platelets &lt; 100000/microl Hodgkin´s Disease `` composite lymphoma '' Activity index ( WHO ) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Hodgkin´s Lymphoma</keyword>
	<keyword>advanced stage</keyword>
</DOC>